Exercise Training in High-Risk Populations: A Scientific Statement From the American Heart Association
Listen to this summary
This scientific statement from the American Heart Association addresses the unique considerations and challenges of exercise training in high-risk populations, such as those with frailty or advanced heart conditions. The authors aim to identify the barriers to participation, necessary modifications to exercise programs, and the potential benefits of tailored interventions, highlighting the need for further research to develop effective, patient-centered exercise regimens for these groups. Ultimately, the statement seeks to enhance the safety and efficacy of exercise training in populations that may not benefit from traditional approaches.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Circulation
View all →Jul 8, 2026 · Circulation
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association
Jul 6, 2026 · Circulation
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Jun 29, 2026 · Circulation
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Jun 26, 2026 · Circulation
Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry
Jun 24, 2026 · Circulation
Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association
Jun 22, 2026 · Circulation
Challenges and Future Trends in Large Vessel Vasculitis
More in Thoracic Surgery (Cardiothoracic Vascular Surgery)
View all →Jul 10, 2026 · Lancet (London, England)
Advancing the relevance of clinical trials for older patients
Jul 9, 2026 · Lancet (London, England)
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
Jul 9, 2026 · JAMA
Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States
Jul 9, 2026 · Lancet (London, England)
Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations
Jul 9, 2026 · Lancet (London, England)
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial
Jul 8, 2026 · The New England journal of medicine
Meningococcal B Vaccine to Prevent <em>Neisseria gonorrhoeae</em> Infection
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


